- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07941713
Respiratory Restriction Leaded by Conventional or Minimally Invasive Sugical Repair of Oesophageal Atresia in Children (RestriMIS2)
Assessment of Respiratory Restriction Caused by Chest Wall Abnormalities Following Conventional or Minimal Invasive Surgical Repair of Type III Esophageal Atresia in School Age Children
Children born with esophageal atresia need surgery shortly after birth. For many years, the standard operation was a thoracotomy, an opening in the chest that can sometimes lead to changes in the shape of the chest wall. Although these changes are visible on X rays, doctors still do not fully understand how much they affect breathing later in childhood. A newer, less invasive technique called thoracoscopy uses small incisions and appears to cause fewer chest deformities, but its impact on lung function has not yet been clearly established.
This study aims to compare the breathing capacity of children aged 6 to 9 who were operated on using either thoracotomy or thoracoscopy. The main question is whether one group is more likely to develop restrictive lung syndrome, a condition in which the lungs cannot expand normally. To answer this, the study relies on lung function tests and chest X rays performed during routine follow up visits.
Beyond this primary goal, the study also examines other possible breathing problems, the presence of chest wall abnormalities, and factors that might influence lung health, such as nutrition, physical activity, associated malformations, and overall quality of life.
A total of at least 360 children across France will participate. They are identified through national registries and invited during scheduled follow up consultations.
Visão geral do estudo
Status
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Francoise SCHMITT, MD
- Número de telefone: +33 2 41 35 42 90
- E-mail: FrSchmitt@chu-angers.fr
Estude backup de contato
- Nome: Josue Rakotonjanahary
- Número de telefone: +33 2 41 35 57 40
- E-mail: JoRakotonjanahary@chu-angers.fr
Locais de estudo
-
-
-
Amiens, França, 80054
- CHU Amiens, Département de Pédiatrie, centre d'activité "chirurgie pédiatrique viscérale"
-
Contato:
- Philippe BUISSON, MD
- Número de telefone: +33 3 22 08 75 60
- E-mail: buisson.philippe@chu-amiens.fr
-
Investigador principal:
- Philippe BUISSON, MD
-
Angers, França, 49933
- CHU Angers, Service Urgences, Médecine, Psychiatrie et Chirurgie Pédiatriques
-
Contato:
- Francoise SCHMITT, MD
- Número de telefone: 2 41 35 42 90
- E-mail: FrSchmitt@chu-angers.fr
-
Contato:
- E-mail: JoRakotonjanahary@chu-angers.fr
-
Investigador principal:
- francoise SCHMITT, MD
-
Clermont-Ferrand, França, 63003
- CHU Clermont-Ferrand, Service de pédiatrie générale et multidisciplinaire
-
Contato:
- Carole Egron, MD
- Número de telefone: +33 4 73 75 00 24
- E-mail: cegron@chu-clermontferrand.fr
-
Investigador principal:
- Carole EGRON, MD
-
Dijon, França, 21000
- CHU Dijon, Service de chirurgie pédiatrique
-
Contato:
- Michel FRANCOIS, MD
- Número de telefone: +33 3 80 28 14 35
- E-mail: michel.françois@chu-dijon.fr
-
Investigador principal:
- Michel FRANCOIS, MD
-
Grenoble, França, 38700
- CHU Grenoble, Service de chirurgie pédiatrique
-
Contato:
- Pierre-Yves RABATTU, MD
- Número de telefone: +33 4 76 76 59 00
- E-mail: pyrabattu@chu-grenoble.fr
-
Investigador principal:
- Pierre-Yves RABATTU, MD
-
Le Kremlin-Bicêtre, França, 94275
- Hôpital Bicêtre, AP-HP, Chirurgie Viscérale Pédiatrique
-
Contato:
- Khadidja KHADIR, MD
- Número de telefone: +33 1 45 21 21 21
- E-mail: khadidja.khadir@aphp.fr
-
Investigador principal:
- Khadidja KHADIR, MD
-
Lyon, França, 69677
- Hospices Civils de Lyon, Service d'Hepato-Gastroentérologie et Nutrition Pédiatrique
-
Contato:
- Nicolas CARON, MD
- Número de telefone: +33 4 72 35 70 50
- E-mail: nicolas.caron@chu-lyon.fr
-
Investigador principal:
- Nicolas CARON, MD
-
Nantes, França, 44093
- CHU Nantes, Hôpital Mère-Enfant, Service de Chirurgie Infantile
-
Contato:
- Audrey GUINOT, MD
- Número de telefone: +33 2 40 08 35 85
- E-mail: audrey.guinot@chu-nantes.fr
-
Investigador principal:
- Audrey GUINOT, MD
-
Paris, França, 75015
- Hôpital Necker Enfants Malades, AP-HP, Service de Pneumologie et Allergologie Pédiatriques
-
Contato:
- Rola ABOU TAAM, MD
- Número de telefone: +33 1 44 38 15 65
- E-mail: rola.aboutaam@aphp.fr
-
Investigador principal:
- Rola ABOU TAAM, MD
-
Strasbourg, França, 67098
- CHU Strasbourg, Service de chirurgie pédiatrique
-
Contato:
- Isabelle TALON, MD
- Número de telefone: +33 3 88 12 73 17
- E-mail: isabelle.talon@chru-strasbourg.fr
-
Toulouse, França, 31059
- CHU Toulouse, Service de Chirurgie Viscérale Pédiatrique
-
Contato:
- Aurélie LE MANDAT, MD
- Número de telefone: +33 5 34 55 85 44
- E-mail: lemandat.a@chu-toulouse.fr
-
Investigador principal:
- Aurelie LE MANDAT, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Eligible patients in both groups are mainly identified through the national esophageal atresia registry (RENATO, CRACMO, CHU Lille).
Descrição
For thoracoscopy group:
Inclusion Criteria:
- Child operated on by thoracoscopy for type 3 AO (excluding long gap) according to Ladd's classification
- Child aged 6 to 10 years old
- Consent from parents (or legal guardians) and the child's agreement to participate in the study
Exclusion Criteria:
- Heart or lung malformation diagnosed at birth and requiring surgery
- Conversion from thoracoscopy to thoracotomy during the procedure
- Child who has had more than one thoracic surgery (reoperation for AO, other reasons for thoracic surgery including heart surgery)
- For Thoracotomy group*:
Inclusion Criteria :
--Child operated on by thoracotomy for type 3 AO (excluding long gap) according to the Ladd classification
- Child aged 6 to 10 years old
- Consent from parents (or legal guardians) and the child's agreement to participate in the study
Exclusion Criteria:
- Heart or lung malformation diagnosed at birth and requiring surgery
- Child who has had more than one thoracic surgery (reoperation for AO, other reason for thoracic surgery including heart surgery)
- Child operated on for type 3 AO via thoracotomy (excluding long gap) according to Ladd's classification
For each patient who underwent thoracoscopic surgery included in the study, two patients who had thoracotomy, matched according to known or suspected confounding factors for restrictive syndromes from the RestriMIS1 (NCT04136795) study**, will be included.
*It's possible that some children had multiple consecutive surgeries. In those cases, if one of the procedures was a thoracotomy, the children will be classified in the thoracotomy group (the more major surgery).
**Prematurity, birth weight, presence of tracheomalacia, and GERD during the neonatal period (clinically and/or on additional tests)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
|---|
|
thoracoscopy group
minimally invasive surgical approach |
|
thoracotomy arm
conventionnal surgical approach |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
to assess the presence of a restrictive lung syndrome in patients with type 3 esophageal atresia (EA) depending on the type of surgical approach used (conventional or minimally invasive).
Prazo: Lung function tests can be done up to 2 years after the multidisciplinary consultation (Visit 0)
|
Rate of restrictive syndrome according to the type of surgical approach (conventional or minimally invasive), defined by spirometry data: FEV1/FVC > -1.64 Z-score and FVC < -1.64 Z-score, according to the ATS/ERS-GLI (American Thoracic Society & European Respiratory Society - Global Lung Initiative) recommendations published in 2012 (Quanjer) and reviewed en 2022. |
Lung function tests can be done up to 2 years after the multidisciplinary consultation (Visit 0)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
to evaluate the importance of restrictive syndrome
Prazo: importance of restrictive syndrome can be evaluated up to 2 years after the multidisciplinary consultation (visit 0)
|
The importance of restrictive syndrome is classified into 3 levels: mild restrictive syndrome [-1.64 > z-score ≥ -2.5], moderate [-2.5 > z-score ≥ -4.0], or severe [-4.0 > z-score]). |
importance of restrictive syndrome can be evaluated up to 2 years after the multidisciplinary consultation (visit 0)
|
|
Looking for other respiratory parameters
Prazo: the link between chest skeletal abnormalities found on chest X-rays and lung impact can be evaluated up to 2 years after the multidisciplinary consultation
|
Other respiratory changes are examined by measuring other respiratory parameters (forced vital capacity, FEF 25-75, Tiffeneau ratio, reversibility), which help highlight obstructive or mixed syndromes (FEV1/FVC < -1.64 and FVC < -1.64 z-score) when present |
the link between chest skeletal abnormalities found on chest X-rays and lung impact can be evaluated up to 2 years after the multidisciplinary consultation
|
|
to assess the link between chest skeletal abnormalities found on chest X-rays and lung impact
Prazo: until spirometry is completed, within a maximum period of 2 years
|
The following factors are considered when estimating the risk of association with or without a restrictive syndrome (history data like prematurity or types of malformations associated with AO III, surgical and medical care data in the neonatal period and childhood, growth data at one year and at 6-10 years), lung care, physical activity, the PedsQL score (for children aged 6 to 10), and responses to the EA-QoL questionnaire (for children aged 8 to 10). |
until spirometry is completed, within a maximum period of 2 years
|
|
rate of postoperative complications and any necessary reoperations
Prazo: up to 2 years after the multidisciplinary consultation
|
The rate of postoperative complications is assessed by type of surgery as well as any necessary follow-up surgeries. |
up to 2 years after the multidisciplinary consultation
|
|
Respiratory-related quality of life during childhood
Prazo: up to 2 years after the multidisciplinary consultation
|
It will be estimated through both need for lung care, physical activity, PedsQL score (for children aged 6 to 10), and EA-QoL questionnaire (for children aged 8 to 10). |
up to 2 years after the multidisciplinary consultation
|
|
to assess the existence of a cause-and-effect link between the restrictive syndrome and the surgical technique used
Prazo: through study completion, within a maximum of 24 months
|
The acceptability of the existence of a causal link is assessed using sensitivity analysis, which estimates how robust the results are while taking into account missing data and different clinical scenarios (including a per-protocol analysis in addition to the intention-to-treat analysis). |
through study completion, within a maximum of 24 months
|
|
to assess the mortality rate
Prazo: through study completion, an average 7 years
|
The death rate for each surgery group will be described based on the follow-up in the study, that is, the date of the surgery (combined data for all patients in the registry). |
through study completion, an average 7 years
|
|
Looking for lung volumes variations
Prazo: the link between chest skeletal abnormalities found on chest X-rays and MRI lung volumes can be evaluated up to 2 years after the multidisciplinary consultation
|
Lung volume variations will be measured by dynamic respiratory MRI data |
the link between chest skeletal abnormalities found on chest X-rays and MRI lung volumes can be evaluated up to 2 years after the multidisciplinary consultation
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 49RC25_0432
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .